Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer

Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer

<i>Background</i>: Hormone receptor-positive and HER2-negative breast cancer (HR + BC) is the most prevalent breast cancer. Endocrine therapy is the mainstay of treatment, however, due to the heterogeneous nature of the disease, resistance to endocrine therapy is not uncommon. Over the p...

Full description

Bibliographic Details
Main Authors: Samitha Andrahennadi, Amer Sami, Mita Manna, Mehrnoosh Pauls, Shahid Ahmed
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Current Oncology
Subjects:
breast cancer
hormone receptor-positive breast cancer
estrogen receptor-positive-breast cancer
systemic therapy
targeted therapy
antiestrogen therapy
Online Access:https://www.mdpi.com/1718-7729/28/3/168

Similar Items

Similar Items